Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sangamo Biosciences (SGMO)
NASDAQ:SGMO
Holding SGMO?
Track your performance easily
Earnings Data
Report Date
Feb 19, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.09Last Year’s EPS
-$0.34Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: -49.45%
|Next Earnings Date:Feb 19, 2025
Earnings Call Sentiment|Positive
The earnings call was positive, highlighting significant regulatory and clinical advancements, as well as strategic partnerships, despite the financial constraints posed by a limited cash runway.Company Guidance
During the Sangamo Therapeutics Q3 2024 earnings call, the executive team provided guidance on several key metrics. They highlighted significant regulatory advancements in their Fabry disease program, noting a clear FDA pathway to accelerated approval, which reduces the time to potential approval by three years. They anticipate a Biologics License Application (BLA) submission in the second half of 2025. Additionally, the company reported receiving $50 million in upfront license fees and milestone payments from a new agreement with Genentech, extending their cash runway into Q1 2025. Sangamo also mentioned the potential to earn up to $220 million in milestone payments from Pfizer for their hemophilia A program over the next two years. The cash runway is projected to last into the first quarter of 2025, absent further funding from collaborations or milestone payments.Regulatory Progress for Fabry Disease Program
Sangamo has aligned with the FDA on a clear regulatory pathway to accelerated approval for their Fabry disease program, reducing the time to potential approval by 3 years and avoiding an additional costly registrational study.
Pfizer Hemophilia A Program Milestone
Pfizer's Phase III AFFINE trial for hemophilia A met its primary endpoint with a significant decrease in total annualized bleeding rate, unlocking potential for $220 million in regulatory and commercial milestones for Sangamo.
Genentech Collaboration and Financial Boost
Sangamo signed a neurology epigenetic regulation and capsid delivery license agreement with Genentech, receiving $50 million in upfront license fees and milestone payments.
First IND Submission for Neurology Indication
Sangamo submitted its first IND application for a neurology indication, with plans for the clinical trial to start in the middle of 2025.
---
SGMO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SGMO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $2.71 | $2.44 | -9.96% |
| Aug 06, 2024 | $0.99 | $0.86 | -13.13% |
| May 09, 2024 | $0.52 | $0.56 | +7.69% |
| Mar 13, 2024 | $0.86 | $0.78 | -9.30% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Sangamo Biosciences (SGMO) report earnings?
Sangamo Biosciences (SGMO) is schdueled to report earning on Feb 19, 2025, TBA Not Confirmed.
What is Sangamo Biosciences (SGMO) earnings time?
Sangamo Biosciences (SGMO) earnings time is at Feb 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SGMO EPS forecast?
SGMO EPS forecast for the fiscal quarter 2024 (Q4) is -$0.09.
---